
On the 29th, the nurses brought Dad the traditional birthday cake, complete with serenade, to celebrate the re-birth of his immune system.
Go cells, go!
Commentary from an Initial Participant in a Phase I/II Trial for the MCL Vaccine at Stanford University


Despite any rumblings that may occur in your, or my, stomach at the sight of these, this is not your father's chemotherapy. I must give kudos to the infusion staff and to Dr. Vinnie Juneja for minimizing much of the potential discomfort of this experience. In many respects, I was able to continue with the regular aspects of my life.
Meanwhile, also on August 17 (give or take a few days), 3,000 miles away, Dr. Josh Brody and the MCL research team at Stanford received approval from the FDA to commence a Phase I study to apply a previously developed vaccine to the treatment of Mantel Cell Lymphoma. In anticipation of all of this, back in April, we spent a day in Palo Alto visiting the hospital and leaving enough blood to construct my own version of the vaccine. The vaccine was made and resides in a freezer somewhere in the vicinity.
So the next chapter in all of this will include administration of that vaccine with a contemporaneous "reconditioning" of my immune system, also known as an Autologous Stem Cell Transplant or SCT. (Used to be called a bone marrow transplant, but technology has overtaken that aspect. It is no longer necessary to invade my skeleton for marrow. Stem cells are, instead, extracted pretty simply from my blood in a process called Apheresis.) The SCT will remove most traces of my lymphoma and place my immune system on a new and rejuvenated footing. The vaccine, which is administered before, during, and after, the transplant will teach my new T cells to recognize and destroy any newly forming MCL cells.